65,437 trials
Type 1 Diabetes Mellitus
Primary: Change From Baseline to 6 Months in Glycosylated Hemoglobin (HbA1c) — -0.14; -0.18 percentage of HbA1c — p=0.4516
Hemorrhoids
Primary: Intraoperative Bleeding — 32; 50 participants — p=0.0001
Glaucoma
Primary: Ocular Tolerance — 65; 34 participants — p=< 0.001
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48 — -2.4; -2.2; -2.4; -2.2 units on a scale
Diabetic Macular Edema
Primary: Change in Best Corrected Visual Acuity (BCVA) Measured Using Early Treatment of Diabetic Retinopathy Study (ETDRS) Methodology at Month 12 Compared to Baseline — 4.9…
Diabetes Mellitus Type II,
Primary: Change From Baseline in HbA1C at 1 Year. — 0.6925; 0.1707 percentage of glycated haemoglobin — p=0.005
Thoracic Aortic Aneurysms
Primary: Primary Safety Observation - Rate of Major Adverse Events (MAEs) — 3 participants
Substance Use Disorders · Alcohol Abuse · Alcoholism
Primary: Abstinence Rate (During the Preceding 90 Days) at 12 Months Follow-up Point as Assessed by the Form-90 — 40; 38; 47; 51 participants
Non Small Cell Lung Carcinoma
Primary: Progression Free Survival — 2.3; 4.0; 2.4; 2.1 Months — p=0.24
Anal Fistula
Primary: Healing Success — 22; 25 participants — p=0.59
Hepatitis C Virus Genotype-1
Primary: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12) — 73.6 percentage of participants
Refractive Error · Myopia · Myopic Astigmatism
Primary: Mean Investigator-Rated Lens Centration — 0.34; 0.73 units on a scale
Cystic Fibrosis
Primary: Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 — 76.3659; 79.3361; 8.1308; -5.8738 percent…
Purulent Bacterial Conjunctivitis
Primary: The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3 — 48; 29 participants
Heart Transplantation
Primary: Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week — 0.0; 0.0; 2.78; 2.78 percentage of participants